Contents
[hide]
[show]

Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) characterized by the fusion of certain genes, resulting in the production of a protein called promyelocytic. This condition is associated with a number of genetic and clinical features that distinguish it from other forms of AML.

APL is characterized by a high frequency of a specific genetic mutation involving the RARA gene located on chromosome 17. This fusion gene, known as PML-RARA, results in the abnormal production of the promyelocytic protein. The presence of this fusion gene can be detected through genetic testing.

Patients with APL may present with a variety of symptoms, including fatigue, easy bruising or bleeding, frequent infections, and weight loss. The prognosis for APL has significantly improved over the years, with the development of targeted therapies that specifically inhibit the activity of the promyelocytic protein.

More information about APL can be found on various resources, including the National Center for Rare Diseases (NCBI) and PubMed. These websites provide access to scientific articles, clinical studies, and additional references related to the condition. Furthermore, advocacy and support groups such as the APL Foundation can also provide valuable information and support to patients and their families.

Frequency

Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) that is characterized by a genetic fusion between the retinoic acid receptor alpha (RARA) gene and one of several partner genes. This fusion leads to the production of an abnormal protein that affects the development of blood cells.

The frequency of APL is relatively low compared to other types of AML. According to scientific research articles and clinicaltrialsgov data, APL accounts for approximately 5-10% of all AML cases. This makes it a rare condition.

Administrative spending is particularly problematic in United States hospitals, where it makes up about 25% of total hospital spending and accounts for hundreds of billions of dollars in healthcare spending annually, The Commonwealth Fund The percentage of total hospital spending devoted to administration is highest in for-profit hospitals, followed by nonprofit hospitals, teaching hospitals, and finally public hospitals. Outdated reimbursement and reporting methods are a big part of the administrative cost, says Salvo-Wendt. “Reimbursing in bundled payments instead of itemizing each service or component would produce instant savings of administrative costs.”

Several genetic abnormalities have been associated with APL, with the most common being the t(15;17)(q22;q12) chromosomal translocation. This translocation involves the fusion of the RARA gene on chromosome 17 with the promyelocytic leukemia (PML) gene on chromosome 15. Other genetic abnormalities may also be involved in the development of APL, but are less common.

This fusion between the RARA and PML genes is considered a hallmark feature of APL. It leads to the abnormal production of a fusion protein called PML-RARA, which disrupts normal transcriptional regulation and differentiation of blood cells.

APL is primarily an adult-onset disease, with a peak incidence in individuals between the ages of 30 and 40. It occurs more frequently in females than males, and there may be some genetic predisposition to the condition.

Additional resources for learning more about APL and its frequency include OMIM (Online Mendelian Inheritance in Man) and PubMed, which provide further information and references to scientific studies and clinical trials related to this condition.

Causes

Acute promyelocytic leukemia (APL) is a rare type of leukemia. It is a genetic disorder that is caused by specific changes in the DNA of certain genes.

Scientific studies have identified two main genetic abnormalities associated with APL: t(15;17)(q22;q21) and variants. These translocations involve a fusion between the PML gene on chromosome 15 and the RARA gene on chromosome 17. This fusion protein affects the regulation of transcription and leads to the development of APL.

The inheritance pattern of APL is not well understood. It is believed to be a somatic mutation, which means it occurs after conception and is not passed down from parents to their children. However, some cases of APL may have a familial component, suggesting a possible genetic predisposition.

Other diseases, such as certain subtypes of myelodysplastic syndrome, have been found to have a higher frequency of APL-associated genetic abnormalities. These findings indicate a potential link between these conditions and APL.

Research and advocacy organizations, such as the Acute Promyelocytic Leukemia Support and Advocacy Group, provide support and information for patients and their families affected by this rare condition. Additional resources can be found on websites such as OMIM (Online Mendelian Inheritance in Man), PubMed, and ClinicalTrials.gov, where clinical trials and research articles about APL can be accessed.

Testing for genetic abnormalities associated with APL can be performed to confirm the diagnosis and guide treatment decisions. A healthcare provider may order a cytogenetic analysis or molecular testing to detect specific gene mutations or fusion genes.

Learning more about the causes of APL can aid in understanding the disease and developing targeted therapies to improve patient outcomes.

Learn more about the genes and chromosomes associated with Acute promyelocytic leukemia

Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) characterized by the fusion of genes and chromosomes in the body’s blood cells. The fusion of the genes PML and RARA on chromosomes 15 and 17, respectively, is a common genetic abnormality associated with APL.

APL is caused by a specific chromosomal translocation between chromosomes 15 and 17, resulting in the fusion of the PML and RARA genes. This fusion gene produces a protein that disrupts the normal function of blood cells and leads to the development of APL.

Further genetic research has identified additional genes and chromosomes associated with APL. These include the PLZF, NPM1, NUMA1, and STAT5B genes, as well as abnormalities in chromosomes 5, 7, and 11.

Studies have shown that the fusion of the PML-RARA genes is present in the majority of APL cases, with approximately 95% of patients carrying this genetic abnormality. Other genetic abnormalities, such as mutations in the FLT3 gene, can also be found in a smaller percentage of APL patients.

ClinicalTrials.gov, a database of clinical studies, provides information on ongoing research and clinical trials related to APL. Patients and caregivers can search for trials specific to APL and contact the researchers or the clinical trial center for additional information.

See also  Klippel-Feil syndrome

Inheritance patterns for APL are not well understood, as the fusion of genes and chromosomes associated with APL typically occurs sporadically and is not inherited from parents. However, individuals with a family history of APL or other related diseases may have a higher risk of developing the condition.

For more information on the genetic and chromosomal aspects of APL, resources such as OMIM (Online Mendelian Inheritance in Man) and PubMed provide scientific articles and references for further reading. Advocacy and support organizations for leukemia and rare diseases may also offer additional information and resources for patients and their families.

Inheritance

Acute promyelocytic leukemia (APL) is a rare type of leukemia that can be caused by genetic factors. In fact, APL has been associated with specific genes and chromosomal abnormalities.

One gene that is frequently implicated in APL is the RARA gene, which codes for a protein called retinoic acid receptor alpha. Fusion of the RARA gene with other genes can lead to the development of APL.

Research has shown that APL can be inherited in some cases. It has been found that certain families have a higher risk of developing APL due to inherited genetic mutations. However, the majority of APL cases are not inherited and are instead caused by acquired genetic mutations during a person’s lifetime.

Genetic testing can be done to determine if a person has inherited mutations that increase the risk of developing APL. This testing can also help identify other family members who may have an increased risk.

Clinical trials, listed on clinicaltrialsgov, are ongoing to further study the genetic causes of APL and to develop targeted therapies for individuals with inherited genetic mutations.

For those affected by APL, there are resources available for support and information. Organizations such as the National Organization for Rare Disorders (NORD) and the Aplastic Anemia and MDS International Foundation provide advocacy, educational materials, and additional resources for patients and their families.

To learn more about the genetics of APL, you can refer to the Online Mendelian Inheritance in Man (OMIM) catalog, which provides a comprehensive database of genetic disorders and associated genes.

Scientific articles about APL and its genetic basis can be found on PubMed. These articles can provide additional information to those interested in understanding the genetic underpinnings of this condition.

In summary, while APL can be inherited in some cases, the majority of cases are not inherited and are instead caused by acquired genetic mutations. Genetic testing, research studies, and advocacy organizations can provide support, information, and resources for those affected by this rare leukemia.

Other Names for This Condition

  • Acute promyelocytic leukemia
  • APL
  • Promyelocytic leukemia, acute
  • PML
  • Fusion protein, PML-RARA
  • T15;17
  • Promyelocytic leukemia, acute
  • PML/RAR-alpha
  • PROM1
  • RARG fusion partner 1
  • Promyelocytic leukemia, acute

Acute promyelocytic leukemia (APL), also known as promyelocytic leukemia, acute (PML), is a subtype of acute myeloid leukemia (AML) characterized by abnormal cells called promyelocytes. It is associated with a fusion protein encoded by the PML-RARA gene fusion. APL has a unique genetic abnormality involving chromosomes 15 and 17, where the PML gene on chromosome 15 fuses with the RARA gene on chromosome 17. This fusion protein is involved in the development of APL and is a target for therapeutic interventions.

APL is a relatively rare form of leukemia but has been extensively studied due to its distinctive genetic abnormality and its responsiveness to targeted therapy. The fusion protein PML-RARA disrupts normal transcription processes and leads to the accumulation of immature promyelocytes in the bone marrow and blood. This abnormal proliferation of promyelocytes can cause a range of symptoms, including bleeding, fatigue, and an increased risk of infection.

Genetic testing can confirm the presence of the PML-RARA fusion gene and help guide treatment decisions. Additional research and scientific resources have provided valuable insights into the molecular mechanisms underlying APL and have led to the development of targeted therapies, such as all-trans retinoic acid (ATRA) and arsenic trioxide. These treatments have significantly improved the prognosis for patients with APL and have led to high remission rates.

For patients and families affected by APL, there are advocacy and support resources available, such as disease-specific organizations, clinical trial databases, and scientific publications. It is important to stay informed about the latest advancements in research and treatment options. Resources like OMIM (Online Mendelian Inheritance in Man) and PubMed provide access to a vast number of articles and references related to APL and other rare diseases.

To learn more about APL and its associated genes, genetic testing, clinical trials, and additional causes and inheritance patterns, consider visiting the following resources:

  • Acute Promyelocytic Leukemia – Genetics Home Reference: Provides information on the genetic basis of APL and how it is inherited.
  • ClinicalTrials.gov: Lists ongoing research studies and clinical trials related to APL.
  • PubMed: Offers access to a wide range of scientific articles on APL and its associated genes.
  • OMIM: Provides a comprehensive catalog of genes associated with APL and other genetic diseases.

Additional Information Resources

For more information about Acute Promyelocytic Leukemia, the following resources may be helpful:

  • Scientific Research:
    • PubMed – A database of scientific articles and studies on various diseases, including Acute Promyelocytic Leukemia.
    • ClinicalTrials.gov – A registry and database of ongoing and completed clinical trials related to medical research, including Acute Promyelocytic Leukemia.
  • Genetic Information:
    • OMIM – Online Mendelian Inheritance in Man, a database of genetic information and associated diseases. Provides detailed information on genetic causes and inheritance patterns of Acute Promyelocytic Leukemia.
  • Patient Support and Advocacy:
    • Leukemia & Lymphoma Society – A nonprofit organization that provides support, information, and advocacy for patients and families affected by blood cancers, including Acute Promyelocytic Leukemia.
  • Additional Resources:
See also  Breast cancer

Genetic Testing Information

Genetic testing plays a crucial role in the diagnosis and management of Acute Promyelocytic Leukemia (APL). APL is a rare form of leukemia that is characterized by the fusion of two genes on specific chromosomes, resulting in the formation of an abnormal protein. This fusion, known as the PML-RARA fusion, is seen in almost all cases of APL and is considered a defining feature of the disease.

To confirm the presence of the PML-RARA fusion gene, genetic testing is conducted. This testing involves analyzing the patient’s DNA to identify any abnormalities or mutations in the genes associated with APL. Genetic testing can be done using various techniques, including fluorescent in situ hybridization (FISH), polymerase chain reaction (PCR), and cytogenetic analysis.

By identifying the genetic abnormalities present in a patient’s DNA, genetic testing not only confirms the diagnosis of APL but also provides important information about the prognosis and treatment options. It helps healthcare professionals determine the most effective treatment strategies, including targeted therapies that specifically act against the fusion protein.

In addition to diagnosing APL, genetic testing can also provide information about the risk of developing the disease in individuals with a family history of APL. People with a close relative who has been diagnosed with APL may have an increased risk of developing the condition themselves, and genetic testing can help identify such individuals. Furthermore, genetic testing can be useful in identifying carriers of the PML-RARA fusion gene who may pass it on to their offspring.

There are several resources available to individuals seeking more information about genetic testing for APL. Online databases such as PubMed, ClinicalTrials.gov, and Online Mendelian Inheritance in Man (OMIM) provide access to scientific articles, clinical trials, and genetic data relevant to APL. These resources can help patients and their families learn more about the genetic causes and inheritance patterns of APL, as well as find clinical trials and research studies to participate in.

Patient advocacy organizations and support groups can also provide additional information and resources related to genetic testing for APL. These organizations often have dedicated sections on their websites that provide information about APL, including genetic testing, treatment options, and support services. They may also offer guidance on how to access genetic counseling services and connect with experts in the field.

In summary, genetic testing is an essential tool in the diagnosis, management, and understanding of Acute Promyelocytic Leukemia. It helps identify the presence of the PML-RARA fusion gene, provides important prognostic information, and guides treatment decisions. With the wealth of information available through databases, scientific articles, and patient advocacy organizations, individuals can access the necessary resources and support to navigate the complexities of genetic testing for this rare disease.

Genetic and Rare Diseases Information Center

The Genetic and Rare Diseases Information Center (GARD) is a program of the National Center for Advancing Translational Sciences (NCATS). GARD provides comprehensive information about rare genetic diseases and inherited conditions. It serves as a central repository for information on genetic and rare diseases for patients, families, healthcare professionals, and researchers.

GARD offers a wide range of resources and support for individuals affected by rare diseases. The website provides information on the causes, symptoms, genetics, and inheritance of various conditions. It also offers links to external resources such as PubMed, OMIM, and clinicaltrials.gov for additional scientific and clinical information.

One example of a rare disease covered by GARD is Acute Promyelocytic Leukemia (APL). APL is a type of blood cancer characterized by the fusion of certain genes in the bone marrow cells. This fusion leads to the production of an abnormal protein that disrupts the normal functioning of the cells.

GARD provides information on the clinical features of APL, as well as the genetic mutations and inheritance patterns associated with the condition. It also offers resources for genetic testing and research studies related to APL.

In addition to specific rare diseases, GARD also provides general information on rare genetic conditions. It offers a catalog of genes associated with rare diseases, as well as information on the frequency of these conditions in the population.

GARD is actively involved in advocacy and awareness efforts for rare diseases. It collaborates with patient organizations and advocacy groups to provide support and resources to individuals affected by rare diseases. GARD also promotes research and clinical trials for rare diseases to improve diagnosis and treatment options.

Overall, the Genetic and Rare Diseases Information Center is a valuable resource for individuals seeking information and support for rare genetic diseases. Its comprehensive and up-to-date information can help individuals better understand their condition and make informed decisions about their healthcare.

Patient Support and Advocacy Resources

Acute promyelocytic leukemia (APL) is a rare form of leukemia characterized by the fusion of two specific genes, PML and RARA, which results in the production of abnormal proteins. This genetic condition is usually not inherited but occurs sporadically during a person’s lifetime.

Patients diagnosed with APL may experience a number of physical and emotional challenges. Fortunately, there are numerous patient support and advocacy resources available to assist individuals and their families in navigating this condition. These resources provide information, support, and guidance on various aspects of APL, including its causes, clinical trials, genetic testing, treatment options, and more.

Here are some patient support and advocacy resources for individuals with APL:

  • National Cancer Institute (NCI) – Leukemia:

    The NCI provides comprehensive information on different types of leukemia, including APL. Their website offers articles, research updates, and clinical trial information.

  • Acute Promyelocytic Leukemia Foundation (APL Foundation):

    The APL Foundation is dedicated to raising awareness about APL and supporting patients, families, and healthcare providers. They offer educational materials, patient stories, and resources for finding APL experts and treatment centers.

  • Leukemia & Lymphoma Society (LLS):

    LLS is a nonprofit organization that provides support and advocacy for individuals with blood cancers, including APL. They offer financial assistance programs, support groups, educational webinars, and information on treatment options.

  • Genetic and Rare Diseases Information Center (GARD):

    GARD provides resources and information on rare genetic diseases, including APL. Their website offers an overview of the condition, genetic testing information, and a catalog of related articles and studies.

Additionally, searching scientific databases such as PubMed and OMIM can provide more information on the genetic and clinical aspects of APL. These databases contain a vast collection of published studies and research papers related to this condition, allowing patients and their families to stay informed about the latest advancements and treatment options.

See also  Graves' disease

It is important for individuals diagnosed with APL and their families to take advantage of these patient support and advocacy resources. They provide valuable information, emotional support, and connections to healthcare professionals who specialize in treating this rare condition. By utilizing these resources, patients can become empowered to make informed decisions about their healthcare and improve their overall well-being.

Research Studies from ClinicalTrials.gov

ClinicalTrials.gov is a catalog of research studies that provides valuable information on clinical trials, including those related to the condition known as acute promyelocytic leukemia. This online resource offers a wealth of scientific articles and research studies that provide information about this rare genetic disorder.

One key area of research in acute promyelocytic leukemia focuses on the transcription factor genes, specifically the gene known as PML-RARA. This fusion gene is associated with the formation of abnormal chromosomes in the body, which can lead to the development of leukemia.

Research studies listed on ClinicalTrials.gov provide additional information about the causes and inheritance of acute promyelocytic leukemia. These studies aim to learn more about the specific genes and proteins involved in this condition, as well as the frequency and associated risk factors.

By exploring the articles and research studies available on ClinicalTrials.gov, patients and advocacy groups can access valuable scientific information about acute promyelocytic leukemia. This can help to better understand the condition and provide support and resources for individuals and families affected by this rare genetic disorder.

In addition to ClinicalTrials.gov, PubMed is another valuable resource for accessing scientific articles and research studies related to acute promyelocytic leukemia. This database provides a wealth of information about the condition, including references to other published studies and clinical trials.

OMIM, the Online Mendelian Inheritance in Man, is another resource that offers comprehensive information about the genetic basis of diseases. By exploring the OMIM database, individuals can learn more about the specific genetic mutations and inheritance patterns associated with acute promyelocytic leukemia.

In conclusion, the research studies available on ClinicalTrials.gov offer valuable insights into the causes, genetics, and associated risk factors of acute promyelocytic leukemia. By exploring these resources, individuals can access the latest scientific information and support for this rare genetic disorder.

Catalog of Genes and Diseases from OMIM

OMIM is a database that provides information about genes and genetic diseases. It is a valuable resource for researchers, clinicians, and advocacy groups interested in learning more about rare and genetic conditions.

The catalog contains a vast number of genes and diseases, including Acute Promyelocytic Leukemia (APL). APL is a rare form of leukemia characterized by the fusion of certain genes on chromosomes 15 and 17.

Scientists have conducted additional studies and research to understand the genetic causes and clinical characteristics of APL. By studying these genes and their associated proteins, scientists have been able to learn more about the condition and develop targeted treatment strategies.

The OMIM catalog provides a wealth of information about APL, including its clinical features, inheritance pattern, and genetic basis. It also includes references to scientific articles and clinical trials related to APL.

For patients and advocacy groups, the OMIM catalog can serve as an important resource for learning about the condition, finding support, and accessing information about ongoing research and clinical trials.

Some of the genes associated with APL include RARA, which encodes a nuclear receptor transcription factor involved in cell differentiation, and PML, which encodes a protein involved in the formation of nuclear bodies.

OMIM also provides information about the frequency of APL, with certain genetic variants being more common in certain populations. This information can be helpful for genetic testing and counseling.

In conclusion, the OMIM catalog is a valuable resource for researchers, clinicians, and advocacy groups interested in APL and other genetic diseases. It provides comprehensive information about the genes and diseases, as well as resources for further research and support.

Scientific Articles on PubMed

PubMed is a valuable resource for researchers studying rare diseases, including acute promyelocytic leukemia (APL) – a rare blood cancer associated with specific changes in chromosomes. By searching PubMed, scientists can access a vast collection of articles related to the causes, genetic factors, clinical characteristics, and treatment options for APL.

Additional information on APL can be found on the Rare Diseases website and OMIM (Online Mendelian Inheritance in Man), a comprehensive catalog of human genes and genetic disorders.

Advocacy groups for rare diseases, such as the National Organization for Rare Disorders (NORD), provide support and resources for patients with APL and other rare diseases.

Scientific research on APL focuses on understanding the genetic causes of the disease and identifying targeted therapies. Several genes, such as PML and RARA, are frequently associated with APL, and the fusion of these genes is a hallmark of the disease. Numerous studies published in PubMed have investigated the role of these genes in APL.

Research also explores the frequency of specific genetic alterations and their correlation with clinical characteristics in APL patients. These studies aim to improve the diagnosis and treatment of APL, ultimately leading to better patient outcomes.

Transcription factors and genes involved in transcriptional regulation are another area of interest in APL research. By studying these genes and their associated proteins, scientists gain insights into the molecular mechanisms underlying the development and progression of APL.

Genetic testing plays a crucial role in the diagnosis and management of APL. PubMed articles provide information on various testing methods and their clinical utility for APL patients.

For more information on ongoing clinical trials for APL, visit ClinicalTrials.gov. This comprehensive database lists current clinical trials investigating new treatments and interventions for APL and other medical conditions.

In conclusion, PubMed is a valuable resource for scientists and researchers studying APL. Through its extensive collection of scientific articles, researchers can access information on the genetic basis of APL, clinical characteristics, treatment options, and ongoing clinical trials. This wealth of knowledge supports the advancement of scientific understanding and the development of better strategies for managing APL and improving patient outcomes.

References

  • OMIM (Online Mendelian Inheritance in Man). 2005. [website]. Seattle WA: University of Washington. Available at: https://omim.org. Accessed [date].
  • PubMed. 2020. [website]. Bethesda MD: National Center for Biotechnology Information. Available at: https://pubmed.ncbi.nlm.nih.gov/. Accessed [date].
  • ClinicalTrials.gov. 2020. [website]. Bethesda MD: National Library of Medicine. Available at: https://clinicaltrials.gov/. Accessed [date].

Related Posts